Troxerutin-Mediated Complement Pathway Inhibition is a Disease-Modifying Treatment for Inflammatory Arthritis.
Debasis Sahu, Subasa Chandra Bishwal, Md Zubbair Malik, Sukanya Sahu, Sandeep Rai Kaushik, Shikha Sharma, Ekta Saini, Rakesh Arya, Archana Rastogi, Sandeep Sharma, Shanta Sen, R K Brojen Singh, Chuan-Ju Liu, Ranjan Kumar Nanda, Amulya Kumar Panda
Frontiers in cell and developmental biology 2022Troxerutin (TXR) is a phytochemical reported to possess anti-inflammatory and hepatoprotective effects. In this study, we aimed to exploit the antiarthritic properties of TXR using an adjuvant-induced arthritic (AIA) rat model. AIA-induced rats showed the highest arthritis score at the disease onset and by oral administration of TXR (50, 100, and 200 mg/kg body weight), reduced to basal level in a dose-dependent manner. Isobaric tags for relative and absolute quantitative (iTRAQ) proteomics tool were employed to identify deregulated joint homogenate proteins in AIA and TXR-treated rats to decipher the probable mechanism of TXR action in arthritis. iTRAQ analysis identified a set of 434 proteins with 65 deregulated proteins (log2 case/control≥1.5) in AIA. Expressions of a set of important proteins (AAT, T-kininogen, vimentin, desmin, and nucleophosmin) that could classify AIA from the healthy ones were validated using Western blot analysis. The Western blot data corroborated proteomics findings. In silico protein-protein interaction study of tissue-proteome revealed that complement component 9 (C9), the major building blocks of the membrane attack complex (MAC) responsible for sterile inflammation, get perturbed in AIA. Our dosimetry study suggests that a TXR dose of 200 mg/kg body weight for 15 days is sufficient to bring the arthritis score to basal levels in AIA rats. We have shown the importance of TXR as an antiarthritic agent in the AIA model and after additional investigation, its arthritic ameliorating properties could be exploited for clinical usability. Copyright © 2022 Sahu, Bishwal, Malik, Sahu, Kaushik, Sharma, Saini, Arya, Rastogi, Sharma, Sen, Singh, Liu, Nanda and Panda.
Citation
Debasis Sahu, Subasa Chandra Bishwal, Md Zubbair Malik, Sukanya Sahu, Sandeep Rai Kaushik, Shikha Sharma, Ekta Saini, Rakesh Arya, Archana Rastogi, Sandeep Sharma, Shanta Sen, R K Brojen Singh, Chuan-Ju Liu, Ranjan Kumar Nanda, Amulya Kumar Panda. Troxerutin-Mediated Complement Pathway Inhibition is a Disease-Modifying Treatment for Inflammatory Arthritis. Frontiers in cell and developmental biology. 2022;10:845457
PMID: 35433699
View Full Text
